Mechanisms responsible for cardiac and skeletal muscle energetic impairment in type 1 diabetes

niversity Hospitals of Birmingham NHS Foundation Trust0 个研究点目标入组 60 人开始时间: 2006年9月18日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•1.Type I diabetes (WHO definition)
•2.HbA1C <9,
•3.No history of chest pain and no evidence of CAD or peripheral vascular disease
•4.Left ventricular ejection fraction over 50%
•5.No evidence of respiratory disease.
•Group1 with diagnosis in the last 3 years and no evidence of microvascular disease.
•Group 2 with 10-15 years since diagnosis (but age matched) and evidence of coronary microvascular dysfunction.
•Are the trial subjects under 18? yes
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•1.Patients < 16years or who cannot provide informed consent
•2.Evidence of significant epicardial coronary artery disease
•3.Evidence of peripheral vascular disease
•4.Abnormal liver function tests
•5.Clinically apparent peripheral neuropathy (for Perhexiline intervention study)
•6.Severe chronic renal failure (creatinine >250) or diabetic nephropathy
•7.Concomitant use of Amiodarone, Quinidine, Haloperidol or Selective serotonin (5HT) uptake inhibitors such as Fluoxetine and Paroxetine which may inhibit the CYP2D6 enzyme
•8.Patients on statin therapy for primary dyslipidemia.
•9.Patients with recurrent hypoglycaemia
•10.Women of child bearing age who are not using effective contraception (or if pregnancy test positive)

发起方

niversity Hospitals of Birmingham NHS Foundation Trust